Literature DB >> 31647329

Identification of a New Eight-Long Noncoding RNA Molecular Signature for Breast Cancer Survival Prediction.

Yaqiong Zhang1, Zhaoyun Li1, Meifang Chen2, Hanjun Chen1, Qianyi Zhong1, Lingzhi Liang1, Bo Li3.   

Abstract

Because of the phenotypic and molecular diversity, it is still difficult to predict breast cancer prognosis. This study aimed to develop and validate a multi-lncRNA (long noncoding RNA) signature to improve the survival prediction for breast cancer. Three hundred twenty-seven breast cancer patients from GSE20685 were used as a training set. GSE88770 including 117 patients and The Cancer Genome Atlas datasets including 1077 patients were used as 2 validation sets. Kaplan-Meier curve, the LASSO (least absolute shrinkage and selection operator) method, univariate and multivariate Cox analyses were applied to build a molecular model for predicting survival. Function analysis of this lncRNA signature was investigated. A novel eight-lncRNA molecular signature was first identified from multiple datasets. This signature classified patients into the high-risk and low-risk groups. Breast cancer in the high-risk group showed significantly worse survival than that in the low-risk group. Further multivariate Cox analysis revealed that this molecular signature was an independent prognostic factor for breast cancer in the training and validation sets. Furthermore, stratification analyses showed that this molecular signature was also used to classify patients into the low- and high-risk groups in patients with low or high T-stage, patients with or without lymph node metastasis, older or younger, estrogen receptor-positive or -negative, and progesterone receptor-positive or -negative patients. Our eight-lncRNA signature was a powerful tool in predicting prognosis in Luminal B breast cancer based on molecular subtype. This lncRNA signature involved in cell adhesion, apoptosis, cell differentiation, and immune regulation. Our study provided a reliable eight-lncRNA molecular signature for survival prediction of breast cancer, and this signature can stratify patients into the high- and low-risk groups. This molecular signature may help the selection of the suitable treatment strategies.

Entities:  

Keywords:  breast cancer; immune regulation; lncRNA; molecular signature; survival

Year:  2019        PMID: 31647329     DOI: 10.1089/dna.2019.5059

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  6 in total

1.  Long Intergenic Non-Coding RNA LINC00922 Aggravates the Malignant Phenotype of Breast Cancer by Regulating the microRNA-424-5p/BDNF Axis.

Authors:  Xin Yue; Zhuo Wang
Journal:  Cancer Manag Res       Date:  2020-08-21       Impact factor: 3.989

2.  Identification of CD4+ Conventional T Cells-Related lncRNA Signature to Improve the Prediction of Prognosis and Immunotherapy Response in Breast Cancer.

Authors:  Shipeng Ning; Jianbin Wu; You Pan; Kun Qiao; Lei Li; Qinghua Huang
Journal:  Front Immunol       Date:  2022-05-04       Impact factor: 8.786

3.  Four Immune-Related Long Non-coding RNAs for Prognosis Prediction in Patients With Hepatocellular Carcinoma.

Authors:  Muqi Li; Minni Liang; Tian Lan; Xiwen Wu; Wenxuan Xie; Tielong Wang; Zhitao Chen; Shunli Shen; Baogang Peng
Journal:  Front Mol Biosci       Date:  2020-12-08

4.  Construction of an HCC recurrence model basedon the investigation of immune-relatedlncRNAs and related mechanisms.

Authors:  Xiang-Xu Wang; Li-Hong Wu; Liping Ai; Wei Pan; Jing-Yi Ren; Qiong Zhang; Hong-Mei Zhang
Journal:  Mol Ther Nucleic Acids       Date:  2021-11-10       Impact factor: 8.886

5.  A novel biomarker NIFK-AS1 promotes hepatocellular carcinoma cell cycle progression through interaction with SRSF10.

Authors:  Huibin Song; Wenjing Li; Sixuan Guo; Zhentao He; Shi Liu; Yongsheng Duo
Journal:  J Gastrointest Oncol       Date:  2022-08

6.  Prediction of Overall Survival Among Female Patients With Breast Cancer Using a Prognostic Signature Based on 8 DNA Repair-Related Genes.

Authors:  Dai Zhang; Si Yang; Yiche Li; Jia Yao; Jian Ruan; Yi Zheng; Yujiao Deng; Na Li; Bajin Wei; Ying Wu; Zhen Zhai; Jun Lyu; Zhijun Dai
Journal:  JAMA Netw Open       Date:  2020-10-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.